What is QHSLab Inc's earnings per share (EPS)?

QHSLab Inc (USAQ) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a 166.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

QHSLab Inc Financials

USAQ

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows QHSLab Inc (USAQ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.39x

For every $1 of reported earnings, QHSLab Inc generates $0.39 in operating cash flow ($178K OCF vs $457K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

0.6x

QHSLab Inc earns $0.6 in operating income for every $1 of interest expense ($131K vs $237K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.7M

YoY+26.3%

5Y CAGR+84.9%

QHSLab Inc generated $2.7M in revenue in fiscal year 2025. This represents an increase of 26.3% from the prior year.

EBITDA

$222K

YoY-37.0%

QHSLab Inc's EBITDA was $222K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.0% from the prior year.

Net Income

$457K

YoY+276.4%

QHSLab Inc reported $457K in net income in fiscal year 2025. This represents an increase of 276.4% from the prior year.

EPS (Diluted)

$0.02

YoY+166.7%

QHSLab Inc earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 166.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

15M

YoY+39.1%

5Y CAGR+18.0%

10Y CAGR+9.6%

QHSLab Inc had 15M shares outstanding in fiscal year 2025. This represents an increase of 39.1% from the prior year.

Margins & Returns

Gross Margin

67.3%

YoY+3.6pp

5Y CAGR+27.0pp

QHSLab Inc's gross margin was 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.6 percentage points from the prior year.

Operating Margin

4.9%

YoY-4.8pp

5Y CAGR+225.8pp

QHSLab Inc's operating margin was 4.9% in fiscal year 2025, reflecting core business profitability. This is down 4.8 percentage points from the prior year.

Net Margin

17.0%

YoY+29.1pp

5Y CAGR+279.9pp

QHSLab Inc's net profit margin was 17.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 29.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$485K

YoY+64.7%

5Y CAGR+37.6%

QHSLab Inc invested $485K in research and development in fiscal year 2025. This represents an increase of 64.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

USAQ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.7M+26.3%	$2.1M+51.3%	$1.4M+13.3%	$1.2M-12.1%	$1.4M+1035.8%	$125K
Cost of Revenue	$881K+13.8%	$774K+25.8%	$615K-1.3%	$624K-16.1%	$744K+899.0%	$74K
Gross Profit	$1.8M+33.4%	$1.4M+71.1%	$794K+28.1%	$620K-7.6%	$671K+1239.0%	$50K
R&D Expenses	$485K+64.7%	$294K+37.6%	$214K+12.6%	$190K+109.2%	$91K-7.5%	$98K
SG&A Expenses	$439K+58.8%	$276K+6.7%	$259K-33.1%	$388K-14.6%	$454K+244.6%	$132K
Operating Income	$131K-36.2%	$206K+185.7%	-$240K+57.2%	-$561K-11.6%	-$502K-82.6%	-$275K
Interest Expense	$237K-48.9%	$465K+101.8%	$230K-46.8%	$433K+75.8%	$246K+695.5%	$31K
Income Tax	N/A	N/A	N/A	$0	N/A	N/A
Net Income	$457K+276.4%	-$259K+44.6%	-$468K+53.0%	-$996K-29.3%	-$770K-135.2%	-$327K
EPS (Diluted)	$0.02+166.7%	$-0.03+40.0%	$-0.05+54.5%	$-0.11	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$737K+21.7%	$605K-6.2%	$645K+3.1%	$626K+15.0%	$544K+15.1%	$473K-3.2%	$489K+55.1%	$315K
Cost of Revenue	$243K+17.9%	$206K-4.2%	$215K+0.8%	$214K+19.4%	$179K+0.3%	$179K-11.8%	$202K+61.8%	$125K
Gross Profit	$494K+23.7%	$399K-7.2%	$430K+4.3%	$412K+12.9%	$365K+24.0%	$294K+2.9%	$286K+50.7%	$190K
R&D Expenses	$133K+18.2%	$112K-9.4%	$124K+15.3%	$108K+35.3%	$80K+22.7%	$65K+52.0%	$43K-4.2%	$45K
SG&A Expenses	$64K-35.1%	$99K-36.6%	$156K+86.5%	$83K+49.7%	$56K+17.4%	$47K-47.2%	$90K+68.7%	$53K
Operating Income	$96K+735.1%	$12K+195.7%	-$12K-116.5%	$73K-18.0%	$89K+197.3%	$30K+120.3%	$14K+128.1%	-$48K
Interest Expense	$63K-2.5%	$64K-4.6%	$68K-81.3%	$361K+817.3%	$39K+19.7%	$33K+2.3%	$32K-15.9%	$38K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$33K+163.1%	-$53K+33.5%	-$80K+72.3%	-$288K-677.9%	$50K+1822.0%	-$3K+84.4%	-$19K+78.6%	-$87K
EPS (Diluted)	$0.00	$0.00+100.0%	$-0.01	N/A	$0.00	$0.00	$0.00	N/A

USAQ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$1.8M+7.0%	$1.7M-14.1%	$2.0M-11.4%	$2.2M+641.4%	$298K
Current Assets	N/A	$421K+169.5%	$156K-45.3%	$286K-35.9%	$446K+67.5%	$266K
Cash & Equivalents	N/A	$157K+204.7%	$52K-71.1%	$179K-37.7%	$287K+204.1%	$94K
Inventory	N/A	$42K+65.9%	$25K-51.4%	$52K-21.1%	$66K-34.1%	$100K
Accounts Receivable	N/A	$196K+174.7%	$71K+49.5%	$48K-32.3%	$70K+16.4%	$61K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$2.4M+17.0%	$2.1M+9.3%	$1.9M+35.9%	$1.4M+52.8%	$906K
Current Liabilities	N/A	$2.4M+17.0%	$2.1M+20.5%	$1.7M+95.1%	$875K+307.7%	$215K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$608K-61.8%	-$376K-592.6%	$76K-90.7%	$824K+235.5%	-$608K
Retained Earnings	N/A	-$4.3M-8.7%	-$4.0M-13.3%	-$3.5M-39.5%	-$2.5M-44.0%	-$1.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.7M+1.4%	$1.7M+2.5%	$1.7M-7.3%	$1.8M+2.0%	$1.8M+3.9%	$1.7M-1.9%	$1.7M+3.0%	$1.7M
Current Assets	$429K+11.0%	$386K+18.5%	$326K-22.6%	$421K+20.5%	$349K+41.9%	$246K+1.5%	$242K+55.3%	$156K
Cash & Equivalents	$158K-5.9%	$168K+175.7%	$61K-61.1%	$157K+63.8%	$96K-7.9%	$104K+55.7%	$67K+29.8%	$52K
Inventory	$27K-37.0%	$42K+44.8%	$29K-30.1%	$42K+4.4%	$40K+543.9%	$6K-83.2%	$37K+47.4%	$25K
Accounts Receivable	$210K+41.8%	$148K-24.0%	$195K-0.6%	$196K-1.1%	$198K+50.7%	$132K+0.5%	$131K+83.4%	$71K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-0.4%	$2.4M+4.2%	$2.3M-6.1%	$2.4M+14.6%	$2.1M+0.8%	$2.1M-1.4%	$2.1M+2.7%	$2.1M
Current Liabilities	$2.3M-0.4%	$2.4M+4.2%	$2.3M-6.1%	$2.4M+15.2%	$2.1M+0.3%	$2.1M-1.4%	$2.1M+2.7%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$611K+5.2%	-$644K-9.0%	-$591K+2.7%	-$608K-81.3%	-$335K+12.9%	-$385K-0.8%	-$382K-1.7%	-$376K
Retained Earnings	-$4.4M+0.7%	-$4.5M-1.2%	-$4.4M-1.8%	-$4.3M-7.9%	-$4.0M+1.2%	-$4.1M-1.6%	-$4.0M-0.5%	-$4.0M

USAQ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$178K+25.1%	$142K+189.2%	-$160K+54.5%	-$351K+1.1%	-$355K-114.3%	-$166K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$37K+76.0%	-$155K-387.6%	-$32K
Financing Cash Flow	$301K+916.5%	-$37K-213.3%	$33K-88.4%	$280K-60.1%	$702K+161.9%	$268K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$3K-98.0%	$127K+356.4%	-$50K-190.0%	$55K+197.3%	-$57K-164.7%	$87K+54.5%	$57K+141.9%	-$135K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$13K+36.3%	-$20K+57.6%	-$47K-854.2%	$6K-87.2%	$48K+196.4%	-$50K-21.6%	-$41K-130.2%	$137K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

USAQ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	67.3%+3.6pp	63.7%+7.4pp	56.3%+6.5pp	49.8%+2.4pp	47.4%+7.2pp	40.2%
Operating Margin	4.9%-4.8pp	9.7%+26.7pp	-17.0%+28.1pp	-45.1%-9.6pp	-35.5%+185.4pp	-220.9%
Net Margin	17.0%+29.1pp	-12.2%+21.1pp	-33.2%+46.9pp	-80.1%-25.7pp	-54.4%+208.4pp	-262.9%
Return on Equity	N/A	N/A	N/A	-1306.3%-1212.9pp	-93.5%	N/A
Return on Assets	N/A	-14.4%+13.4pp	-27.9%+23.0pp	-50.9%-16.0pp	-34.9%+75.0pp	-109.9%
Current Ratio	N/A	0.17+0.1	0.08-0.1	0.17-0.3	0.51-0.7	1.24
Debt-to-Equity	N/A	-3.96+1.5	-5.48-30.1	24.67+23.0	1.68+3.2	-1.49
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	67.0%+1.1pp	65.9%-0.7pp	66.6%+0.8pp	65.8%-1.2pp	67.1%+4.8pp	62.2%+3.7pp	58.6%-1.7pp	60.3%
Operating Margin	13.1%+11.2pp	1.9%+3.8pp	-1.9%-13.5pp	11.7%-4.7pp	16.4%+10.0pp	6.3%+3.5pp	2.8%+18.1pp	-15.4%
Net Margin	4.5%+13.3pp	-8.8%+3.6pp	-12.3%+33.6pp	-45.9%-55.1pp	9.1%+9.7pp	-0.6%+3.2pp	-3.8%+23.7pp	-27.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	1.9%+5.0pp	-3.1%+1.7pp	-4.8%+11.2pp	-16.0%-18.8pp	2.8%+3.0pp	-0.2%+0.9pp	-1.1%+4.1pp	-5.1%
Current Ratio	0.18+0.0	0.16+0.0	0.14-0.0	0.170.0	0.17+0.0	0.120.0	0.11+0.0	0.08
Debt-to-Equity	-3.84-0.2	-3.65+0.2	-3.82+0.1	-3.96+2.3	-6.26-0.9	-5.41+0.1	-5.53-0.1	-5.48
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ir-Med Inc IRME

$560K

Therma Bright Inc TBRIF

$2.3M

Bionoid Pharma Inc BINP

$1.6M

Cyduct Diagnostics Inc CYDX

$3.9M

Kelyniam Global Inc KLYG

$7.6M

Frequently Asked Questions

What is QHSLab Inc's annual revenue?

QHSLab Inc (USAQ) reported $2.7M in total revenue for fiscal year 2025. This represents a 26.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is QHSLab Inc's revenue growing?

QHSLab Inc (USAQ) revenue grew by 26.3% year-over-year, from $2.1M to $2.7M in fiscal year 2025.

Is QHSLab Inc profitable?

Yes, QHSLab Inc (USAQ) reported a net income of $457K in fiscal year 2025, with a net profit margin of 17.0%.

What is QHSLab Inc's EBITDA?

QHSLab Inc (USAQ) had EBITDA of $222K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is QHSLab Inc's gross margin?

QHSLab Inc (USAQ) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is QHSLab Inc's operating margin?

QHSLab Inc (USAQ) had an operating margin of 4.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is QHSLab Inc's net profit margin?

QHSLab Inc (USAQ) had a net profit margin of 17.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is QHSLab Inc's operating cash flow?

QHSLab Inc (USAQ) generated $178K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does QHSLab Inc spend on research and development?

QHSLab Inc (USAQ) invested $485K in research and development during fiscal year 2025.

How many shares does QHSLab Inc have outstanding?

QHSLab Inc (USAQ) had 15M shares outstanding as of fiscal year 2025.

Are QHSLab Inc's earnings high quality?

QHSLab Inc (USAQ) has an earnings quality ratio of 0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can QHSLab Inc cover its interest payments?

QHSLab Inc (USAQ) has an interest coverage ratio of 0.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.